Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496365 · ClinicalTrials.gov registry record · Phase 2
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
A Phase 2 study of Diabetic Peripheral Neuropathy, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 452
- Enrollment target
- 20
- Study locations
NCT01496365 is a Phase 2 study of Diabetic Peripheral Neuropathy that has completed, run by Daiichi Sankyo. The registered enrollment target is 452 participants, above the 102-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (343% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT01496365, a Phase 2 study of Diabetic Peripheral Neuropathy, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 452 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability and effectiveness of DS-5565 compared to placebo (inactive substance) and pregabalin in diabetic subjects with DPN.
Conditions Studied
Interventions
- DRUG Placebo tablet
- DRUG placebo capsule
- DRUG DS-5565 tablet
- DRUG pregabalin capsule
Study Locations (20)
California
- - Buena Park
- - Burbank
- - Chino
- - Fresno
- - Huntington Beach
- - Lakewood
- - Lomita
- - Long Beach
- - Santa Monica
- - Walnut Creek
Arizona
- - Mesa
- - Phoenix
- - Phoenix
- - Tucson
Alabama
- - Birmingham
- - Huntsville
Arkansas
- - Hot Springs
- - Little Rock
Colorado
- - Boulder
- - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2011-11-28 |
| Est. Completion | 2012-09-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01496365
The ClinicalTrials.gov registry entry for NCT01496365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 452 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (343% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Peripheral Neuropathy appearing as the primary indexed condition, and to 4 interventions - of which Placebo tablet is the first listed.
NCT01496365 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT01496365 about?
NCT01496365 is a clinical study titled "Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy". The purpose of this study is to evaluate the safety, tolerability and effectiveness of DS-5565 compared to placebo (inactive substance) and pregabalin in diabetic subjects with DPN.
What is the current status of trial NCT01496365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 452 participants. The study started on 2011-11-28. Estimated completion is 2012-09-07.
What conditions does trial NCT01496365 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathy.
What interventions are being tested in trial NCT01496365?
The interventions under investigation include: Placebo tablet (DRUG), placebo capsule (DRUG), DS-5565 tablet (DRUG), pregabalin capsule (DRUG).
Who is sponsoring clinical trial NCT01496365?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01496365 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
COMPLETED · Phase 2
-
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
COMPLETED · Phase 2
-
Walking Function in Diabetic Peripheral Neuropathy
RECRUITING · NA
-
Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy
RECRUITING · NA
-
Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individuals With Diabetic Peripheral Neuropathy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.